MFG
CRSP icon

Menard Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Menard Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,888
Closed -$211K – 153
2021
Q3 		$211K Buy
1,888
+279
+17% +$35K 0.18% 151
2021
Q2 		$260K Buy
+1,609
New +$196K 0.25% 119
2021
Q1 		– Sell
-2,289
Closed -$350K – 140
2020
Q4 		$350K Buy
+2,289
New +$271K 0.38% 83

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Menard Financial Group's CRSP Position: Q4 2021 in Review

Menard Financial Group sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,888 shares — an estimated $211K sold.

Menard Financial Group first reported a position in CRSP in Q4 2020 and held it in 3 quarters. The position peaked at $350K in Q4 2020. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Menard Financial Group reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Menard Financial Group sold 1,888 CRISPR Therapeutics shares in Q4 2021, an estimated $211K.
  • Menard Financial Group first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 3 quarters.
  • Menard Financial Group's CRISPR Therapeutics position peaked at $350K in Q4 2020.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Menard Financial Group's 13F filing for Q4 2021, filed 14 Feb 2022.